site stats

Jonathan c. trent md phd npi

NettetJonathan C Trent II, MD, PhD is a Hematology / Oncology Specialist - General practicing in Miami, FL. He has not yet shared a personalized biography with Doctor.com. … Nettet22. mar. 2013 · The NPI number of this provider is 1356683734 and was assigned on March 2013. The practitioner's primary taxonomy code is 2084N0008X with license …

Phase I Study of the Mutant IDH1 Inhibitor Ivosidenib: Safety and ...

Nettet1. feb. 2011 · The NPI number assigned to Dr. Jonathan Magruder M.D. is 1427354810, registered as an "individual" on February 01, 2011 Where is Dr. Jonathan Magruder M.D. located? The provider is located at 242 King Avenue Suite 230 Athens, Ga 30606 and the phone number is (706) 475-1700 Which is Dr. Jonathan Magruder M.D. specialty? NettetDr. Jonathan Trent II, MD is an oncologist in Miami, Florida. He is affiliated with University of Miami Hospital and Clinics, University of Miami Hospital, and Jackson Health … eagles boards https://norriechristie.com

ExpertPerspectives

Nettet19. nov. 2024 · Jonathan C. Trent, MD, PhD, professor and associate director for Clinical Research at the Sylvester Comprehensive Cancer Center, University of Miami Health System, discusses the... Nettet24. mar. 2024 · The accumulation of 2-HG contributes to malignancy via epigenetic pathways, although the precise mechanism remains unclear. 2-HG competitively inhibits a-KG–dependent NettetJonathan C. Trent, MD, PhD Until recently, there were only 3 drugs that were approved by the US Food and Drug Administration for patients with unresectable or metastatic GIST: imatinib, sunitinib, and regorafenib. More recently, ripretinib was shown to have a 6.3-month median progression-free survival (PFS) in the fourth-line setting or beyond. csl southfield mi

Similar to JONATHAN C. TRENT II M.D., PH. D. NPI 1780770552

Category:Jonathan Robert Brent, MD, PhD Northwestern Medicine

Tags:Jonathan c. trent md phd npi

Jonathan c. trent md phd npi

Dr. Jonathan Trent II, MD – Miami, FL Oncology

NettetJonathan C Trent Ii, MD, PH D is a medicare enrolled "Internal Medicine - Medical Oncology" physician in Miami, Florida. He went to University Of Texas Medical School …

Jonathan c. trent md phd npi

Did you know?

NettetJonathan C. Trent, MD, PhD The symptoms of GIST can be somewhat vague and nonspecific, and there may be no symptoms early on because of submucosal localization and noninvasive behavior. Patients with GIST might initially be thought to have irritable bowel syndrome, anemia, gastric ulcers, gallbladder disease, or any number of … NettetJonathan C. Trent, MD, PhD. Professor of Medicine Associate Director for Clinical Research Sylvester Comprehensive Cancer Center University of Miami Miller School of Medicine Miami, FL “Some of the potential side effects of TKIs are common to all of the agents that we use for GIST.

Nettet26. jun. 2024 · Jonathan C. Trent, MD, PhD. Anlotinib, a novel tyrosine kinase inhibitor capable of mounting a multipronged attack against oncogenic processes, is being tested in rare soft tissue sarcoma subtypes ... Nettet7. aug. 2024 · Jonathan C. Trent, MD, PhD, professor and associate director for Clinical Research at the Sylvester Comprehensive Cancer Center, University of Miami Health System, discusses the role of ...

Nettet21. apr. 2024 · Jonathan Trent, MD, PhD: Larotrectinib certainly is the first NRTK inhibitor that was studied. It has been studied in a number of studies, and researchers have looked at many subsets in this entity. Nettet19. mar. 2024 · Jonathan C. Trent, MD, PhD, discusses the utility of circulating tumor DNA to understand primary driver mutations in gastrointestinal stromal tumor.

Nettet7. aug. 2024 · Jonathan C. Trent, MD, PhD, professor and associate director for Clinical Research at the Sylvester Comprehensive Cancer Center, University of Miami Health …

Nettet4. aug. 2024 · Jonathan C. Trent, MD, PhD, recently discussed the treatment considerations he makes when treating patients with gastrointestinal stromal tumors (GIST). Trent discussed his treatment decisions based on 2 case scenarios during a Targeted Oncology live case-based peer perspectives dinner. csl speed 4628Nettet17. mar. 2024 · Jonathan C. Trent, MD, PhD. Soft tissue sarcoma treatments have significantly advanced within the past year with new available agents, others in the pipeline, and the continued search for ... csl speditionNettet8. apr. 2024 · Jonathan C. Trent, MD, PhD Professor of Medicine, Sarcoma Medical Oncology Program, University of Miami, Sylvester Comprehensive Cancer Center, Miami, Florida Correspondence: [email protected] Disclosure + Editor Charlotte Warren Scientific Director, Medscape, LLC Disclosure + Nafeez Zawahir, MD CME Clinical … eagles board gameNettet5. okt. 2006 · JONATHAN C. TRENT II M.D., PH. D. Location Address: 1475 NW 12TH AVE MIAMI, FL 33136: Location Phone (305) 243-1000: Mailing Address: 1611 NW … csl speechNettetDr. Jonathan C. Trent is a board-certified oncologist who has dedicated his career to researching and treating cancer. An Oklahoma native, Dr. Trent attended Southeastern … csls oxfordNettetJonathan C Trent MD PhD Miller School of Medicine Home Faculty Jonathan C Trent MD PhD Jonathan C Trent, M.D., Ph.D., Department: Medicine Division: Medical … csl speed v25513NettetNPI Number Lookup is the premier NPI database in the country with up-to-date information from the latest National Provider Identifier (NPI) records. Launched in 2007, NPI … csl speed 4639